Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
(Tromsø, 26 April 2019) Biotec Pharmacon's ("Biotec", OSE: BIOTEC) subsidiary Biotec BetaGlucans has entered into a distribution agreement for Woulgan® with the Austrian distributor Publilog GmbH (Publilog).
Under the terms of the agreement, Publilog becomes an exclusive partner for distribution of Woulgan® to the Austrian market, with Biotec supporting Publilog's marketing division. Publilog is a subsidiary of the Swiss based Publicare Group - a leading homecare company in the D-A-CH region.
Woulgan® is a premium-priced product targeting hard to heal wounds in the professional wound care market. Clinical experience with Woulgan® demonstrates significantly improved healing, less pain and improved comfort during the treatment period compared to most common therapies.
This agreement align with the newly revised go-to-market strategy for Woulgan®, which focusses on launching and finding new partners in more countries.
Christian Jørgensen, CEO, said:
"We are pleased to see that Woulgan is generating interest in other parts of Europe, building on the increasing success we have been seeing in Germany. By entering into this new distribution agreement, we are delivering on our amended strategy to strenghten Woulgan's market presence."
Finn Ketler, VP Wound Care, said:
"By signing Publilog as our exclusive distributor in Austria, our market reach extends beyond our initial core markets. We expect that Woulgan will be reimbursed from January 1st, 2020, subject to regulatory processes, so sales are likely to start having an impact from the end of this year."
Wolfgang Baumgartner, CEO Publilog GmbH, said
We are proud by signing the contract with Biotec Pharmacon because our intention is to bring new, unique products with high potential for the treatment of chronic wounds to the Austrian market. We started this way two years ago and continue now consistently.
-ENDS-
For more information, please contact:
Biotec Pharmacon
CEO Christian Jørgensen Tel: +47 47 79 24 57
Email: ir@biotec.no
Instinctif Partners
Melanie Toyne-Sewell / Dr Tel: +44 207 457 2020
Christelle Kerouedan / Biotecpharmacon@instinctif.com
Deborah Bell
About Biotec Pharmacon ASA
Biotec Pharmacon is a Norwegian life sciences company focused on specialized, novel enzyme and immunomodulating beta-glucan technology.
The Biotec Pharmacon Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsoe to offer niche and high tech products in several biotech segments.
ArcticZymes develops, manufactures and commercialises novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.
Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans addressing high unmet healthcare needs, such as chronic wound healing and as an adjuvant in vaccines against certain types of cancer relapse.
Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.
Biotec Pharmacon's unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products.
For more information, please visit the website: www.biotec.no.
About Biotec BetaGlucans
BetaGlucans develops, produces and markets immunomodulating beta-1,3/1,6-glucan (BG) products derived from the cell wall of the Saccharomyces cerevisiae.
The active pharmaceutical ingredients display immunomodulatory properties addressing high unmet healthcare needs, such as chronic wound healing or cancer.
Soluble BetaGlucan (SBG®) has been developed as the active ingredient in the wound healing product (Woulgan®) and is also being tested in a R&D programme as an adjuvant for immunotherapeutic cancer treatments.
For more information, please visit: https://biotec.no/about-us/biotec-betaglucans/.